iSelect Fund
  • Portfolio
  • Team
  • Focus Areas
    • Food & Agriculture
    • Healthcare
    • Food is Health
    • Soil Health
    • Impact Investing
    • Entrepreneurs
  • Invest
  • Insights
  • Contact
  • My iSelect
    • My iSelect Login
Select Page

Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair

Read more

Indalo Therapeutics Presents Phase 1 Clinical Trial Results for Lead Antifibrotic Drug Candidate IDL-2965

Read more

Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965

Read more

Indalo Therapeutics Starts Phase 1 Trial Testing Antifibrotic Candidate IDL-2965

Read more

VC-backed Indalo Therapeutics taps Jacks as president and CEO

Read more
Indalo Targets Idiopathic Pulmonary Fibrosis

Indalo Targets Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis is a highly progressive and life threatening disease affects approximately 130,000 people in the United States.  It’s worse than many cancers.  According to the National Institute of Health, physicians are unsure of the cause, but the... Read more

Related Posts

  • startups
    Empowering Entrepreneurs and Their Success
  • what investors look for
    This Is What the Ideal iSelect Company Looks Like
  • Neuros Medical Nerve Block Technology
    iSelect Portfolio: Neuros Medical Closes $20 Million Funding Round
  • Venture Capital Diligence
    What Is the iSelect Diligence Process?
  • BioTech Selection Committee Member, Melissa Walker
    BioTech Selection Committee Member, Melissa Walker
AgTechFund BLOG SIDEBAR

(314) 219-8688

7750 Maryland Ave
Box 11826
St. Louis, MO 63105

Crunchbase   Twitter   LinkedIn   Facebook   YouTube

Securities offered through North Capital Private Securities ("NCPS"), Member FINRA/SIPC, located at 623 East Ft. Union Blvd, Suite 101, Salt Lake City, UT 84047. NCPS does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security offered on or off this investment platform.  Please review North Capital’s Form CRS and its background on FINRA’s BrokerCheck.  Investments in private offerings are speculative, illiquid and involve a high degree of risk and those investors who cannot afford to lose their entire investment and who cannot hold an investment for an indeterminate period should not invest in such offerings. Past performance is not indicative of future results.  All information provided herein should not be relied upon to make an investment decision and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Prospective investors are recommended to consult with a financial adviser, attorney, accountant, and any other professional that can help you understand and assess the risks associated with an investment opportunity. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.